KMDA Logo

Kamada Ltd (KMDA) Stock Forecast & Price Prediction

Live KMDA Stock Price & Analysis

Home โ€บ Stocks โ€บ Israel | NASDAQ | Healthcare | Drug Manufacturers - Specialty & Generic

$7.69

+0.78 (11.29%)

12 Month Price Forecast For KMDA

$7.69
Current Price
$394.27M
Market Cap
2 Ratings
Buy 2
Hold 0
Sell 0
Wall St Analyst Ratings

Distance to KMDA Price Forecasts

+160.1%
To High Target of $20.00
+69.1%
To Median Target of $13.00
+43.0%
To Low Target of $11.00

KMDA Price Momentum

+14.3%
1 Week Change
+5.1%
1 Month Change
+28.6%
1 Year Change
+26.3%
Year-to-Date Change
-3.9%
From 52W High of $8.00
+62.2%
From 52W Low of $4.74

๐Ÿค” Considering Kamada (KMDA)?

Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.

Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.

Data last updated: February 8, 2025 3:55 AM UTC

KMDA Analyst Ratings & Price Targets

Based on our analysis of 3 Wall Street analysts, KMDA has a consensus that is bullish. The median price target is $13.00, with forecasts ranging from $11.00 to $20.00. Currently, there are 2 Buy ratings, 0 Hold ratings, and 0 Sell ratings.

With KMDA currently trading at $7.69, the median price forecast suggests a 69.1% upside. The most optimistic forecast comes from at , projecting a 160.1% upside, while Andrew Fein at HC Wainwright & Co. provides the most conservative target, suggesting a 43.0% upside.

Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.

KMDA Analyst Consensus

2
Buy
0
Hold
0
Sell

KMDA Price Target Range

Low
$11.00
Average
$13.00
High
$20.00
Current: $7.69

Latest KMDA Stock Forecasts by Analyst

These are the latest 20 analyst ratings and price targets for KMDA.

Date Firm Analyst Rating Change Price Target
Jan 10, 2025 HC Wainwright & Co. Andrew Fein Buy Reiterates $11.00
Nov 14, 2024 HC Wainwright & Co. Andrew Fein Buy Reiterates $11.00
Aug 15, 2024 HC Wainwright & Co. Andrew Fein Buy Reiterates $11.00
Jul 3, 2024 Stifel Annabel Samimy Buy Initiates $18.00
May 9, 2024 HC Wainwright & Co. Andrew Fein Buy Reiterates $11.00
Mar 7, 2024 HC Wainwright & Co. Andrew Fein Buy Reiterates $11.00
Nov 14, 2023 HC Wainwright & Co. Andrew Fein Buy Reiterates $11.00
Aug 17, 2023 HC Wainwright & Co. Andrew Fein Buy Reiterates $11.00
May 25, 2023 HC Wainwright & Co. Andrew Fein Buy Reiterates $11.00
Mar 16, 2023 HC Wainwright & Co. Andrew Fein Buy Reiterates $11.00
Feb 2, 2018 Chardan Capital Buy Initiates $7.00
Nov 13, 2015 Jefferies Buy Maintains $8.00
Jun 25, 2013 Morgan Stanley Equal-Weight Initiates $0.00
Jun 25, 2013 Oppenheimer Outperform Initiates $0.00
Jun 25, 2013 Jefferies Buy Initiates $0.00

Stocks Similar to Kamada Ltd

The following stocks are similar to Kamada based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.

Kamada Ltd (KMDA) Financial Data

Kamada Ltd has a market capitalization of $394.27M with a P/E ratio of 25.4x. The company generates $154.57M in trailing twelve-month revenue with a 9.8% profit margin.

Revenue growth is +13.4% quarter-over-quarter, while maintaining an operating margin of +13.3% and return on equity of +7.0%.

Valuation Metrics

Market Cap $394.27M
Enterprise Value $276.22M
P/E Ratio 25.4x
PEG Ratio 22.1x
Price/Sales 2.6x

Growth & Margins

Revenue Growth (YoY) +13.4%
Gross Margin +41.3%
Operating Margin +13.3%
Net Margin +9.8%
EPS Growth +144.3%

Financial Health

Cash/Price Ratio +13.3%
Current Ratio 4.1x
Debt/Equity 3.4x
ROE +7.0%
ROA +3.2%

๐Ÿ”ฅ Want More High-Potential Stock Ideas?

Join 5,000+ investors getting our research on stocks with massive upside potential.

Kamada Ltd logo

Kamada Ltd (KMDA) Company Overview

About Kamada Ltd

What They Do

Manufactures and sells plasma-derived protein therapeutics.

Business Model

The company generates revenue through the production and sale of a wide range of plasma-derived protein therapeutics, as well as the distribution of imported drug products in Israel. Its commercial offerings cater to various medical needs, including prophylactic treatments for infectious diseases, immune system disorders, and chronic conditions.

Additional Information

Kamada Ltd. was established in 1990 and is based in Rehovot, Israel. The company has a diverse product portfolio, providing both proprietary and imported therapies, which positions it well within the biotechnology sector. Its ongoing commitment to innovation and expanding its therapeutic offerings highlights its potential for growth in the healthcare market.

Company Information

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

Employees

378

CEO

Country

Israel

IPO Year

2010

Kamada Ltd (KMDA) Latest News & Analysis

KMDA stock latest news image
Quick Summary

Kamada Ltd. secured a three-year contract for $25 million to supply KAMRABยฎ and VARIZIGยฎ in Latin America for 2025-2027, impacting its 2025 revenue guidance.

Why It Matters

Kamada Ltd.'s $25 million contract for KAMRABยฎ and VARIZIGยฎ enhances revenue visibility and growth potential, positively impacting stock performance and investor confidence.

Source: GlobeNewsWire
Market Sentiment: Neutral
KMDA stock latest news image
Quick Summary

Kamada Ltd. (NASDAQ:KMDA) will hold its Q3 2024 earnings conference call on November 13, 2024, at 08:30 AM ET, featuring key company executives.

Why It Matters

Kamada Ltd.'s upcoming Q3 2024 earnings call may provide insights into financial performance and strategic direction, influencing market sentiment and stock valuation.

Source: Seeking Alpha
Market Sentiment: Neutral
KMDA stock latest news image
Quick Summary

Kamada Ltd. has opened a new 12,000 sq. ft. plasma collection center in Houston, TX, expanding its operations with over 50 donor beds and an annual capacity of 50,000 liters.

Why It Matters

Kamada Ltd.'s new plasma collection center in Houston expands capacity, potentially increasing revenue and market presence in the biopharmaceutical sector, positively impacting stock performance.

Source: GlobeNewsWire
Market Sentiment: Neutral
KMDA stock latest news image
Quick Summary

Kamada Ltd. (NASDAQ: KMDA) will hold its Q2 2024 Earnings Conference Call on August 14, 2024, at 8:30 AM ET, featuring key company executives and financial analysts.

Why It Matters

Kamada Ltd.'s Q2 2024 earnings call indicates upcoming financial insights, potentially impacting stock performance and investor sentiment based on results and guidance.

Source: Seeking Alpha
Market Sentiment: Neutral
KMDA stock latest news image
Quick Summary

Kamada Ltd. (NASDAQ: KMDA) will release its Q2 and first half financial results for 2024 on August 14, 2024, before U.S. market open.

Why It Matters

Kamada Ltd.'s upcoming financial results release could impact stock performance, providing insights into revenue and growth in the biopharmaceutical sector, especially for plasma-derived products.

Source: GlobeNewsWire
Market Sentiment: Neutral
KMDA stock latest news image
Quick Summary

Biotech stocks priced under $10 are highlighted as potentially viable investment opportunities within the biotechnology industry.

Why It Matters

Biotech stocks under $10 may offer high growth potential at lower entry costs, attracting investors seeking value in a sector known for innovation and volatility.

Source: InvestorPlace
Market Sentiment: Positive

Frequently Asked Questions About KMDA Stock

What is Kamada Ltd's (KMDA) stock forecast for 2025?

Based on our analysis of 3 Wall Street analysts, Kamada Ltd (KMDA) has a median price target of $13.00. The highest price target is $20.00 and the lowest is $11.00.

Is KMDA stock a good investment in 2025?

According to current analyst ratings, KMDA has 2 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $7.69. Always conduct your own research and consider your investment goals before making investment decisions.

What is the price prediction for KMDA stock?

Wall Street analysts predict KMDA stock could reach $13.00 in the next 12 months. This represents a 69.1% increase from the current price of $7.69. Please note that this is a projection by Wall Street analysts and not a guarantee.

What is Kamada Ltd's business model?

The company generates revenue through the production and sale of a wide range of plasma-derived protein therapeutics, as well as the distribution of imported drug products in Israel. Its commercial offerings cater to various medical needs, including prophylactic treatments for infectious diseases, immune system disorders, and chronic conditions.

What is the highest forecasted price for KMDA Kamada Ltd?

The highest price target for KMDA is $20.00 from at , which represents a 160.1% increase from the current price of $7.69.

What is the lowest forecasted price for KMDA Kamada Ltd?

The lowest price target for KMDA is $11.00 from Andrew Fein at HC Wainwright & Co., which represents a 43.0% increase from the current price of $7.69.

What is the overall KMDA consensus from analysts for Kamada Ltd?

The overall analyst consensus for KMDA is bullish. Out of 3 Wall Street analysts, 2 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $13.00.

How accurate are KMDA stock price projections?

Stock price projections, including those for Kamada Ltd, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.